Investors Asset Management of Georgia Inc. GA ADV Has $1.47 Million Position in Astrazeneca Plc $AZN

Investors Asset Management of Georgia Inc. GA ADV lessened its holdings in Astrazeneca Plc (NYSE:AZN) by 48.8% during the first quarter, Holdings Channel reports. The fund owned 7,467 shares of the company’s stock after selling 7,123 shares during the period. Investors Asset Management of Georgia Inc. GA ADV’s holdings in Astrazeneca were worth $1,473,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in AZN. MV Capital Management Inc. bought a new position in Astrazeneca during the fourth quarter worth $26,000. Reflection Asset Management acquired a new position in Astrazeneca in the 4th quarter valued at about $31,000. Lloyd Advisory Services LLC. bought a new position in Astrazeneca in the 4th quarter valued at about $35,000. Basepoint Wealth LLC acquired a new stake in Astrazeneca during the fourth quarter worth approximately $44,000. Finally, Acumen Wealth Advisors LLC bought a new stake in shares of Astrazeneca during the fourth quarter worth approximately $47,000. Institutional investors and hedge funds own 20.35% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on AZN. UBS Group reiterated a “buy” rating on shares of Astrazeneca in a research note on Friday, April 10th. TD Cowen restated a “buy” rating on shares of Astrazeneca in a research note on Wednesday, March 18th. Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating on shares of Astrazeneca in a report on Tuesday. Morgan Stanley reissued an “overweight” rating on shares of Astrazeneca in a report on Wednesday, April 8th. Finally, Bank of America reissued a “buy” rating on shares of Astrazeneca in a research report on Wednesday. Fourteen investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $205.33.

Astrazeneca Trading Down 0.1%

AZN opened at $194.96 on Friday. The stock has a market capitalization of $302.36 billion, a price-to-earnings ratio of 29.27, a P/E/G ratio of 1.58 and a beta of 0.24. The company has a quick ratio of 0.71, a current ratio of 0.91 and a debt-to-equity ratio of 0.52. Astrazeneca Plc has a twelve month low of $137.23 and a twelve month high of $212.71. The company has a 50-day simple moving average of $183.96 and a 200 day simple moving average of $187.95.

Astrazeneca (NYSE:AZN) last released its earnings results on Wednesday, April 29th. The company reported $2.58 EPS for the quarter, beating the consensus estimate of $2.52 by $0.06. The firm had revenue of $15.29 billion for the quarter, compared to analyst estimates of $14.93 billion. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. Analysts predict that Astrazeneca Plc will post 10.28 EPS for the current fiscal year.

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.